Dalrada Technology Group(OTC) DFCO

Dalrada helps hospitals, businesses, and homes with pharmacy, clean energy, and technology solutions. Its products support healthcare workers, patients, and companies needing efficient heating or medical supplies. Dalrada’s services aim to make daily operations safer, cleaner, and more reliable for clients worldwide.

What’s in the Dalrada Toolbox?

Genefic (Healthcare, 70.2% of revenue): Pharmacy services, infusion therapies, diagnostic testing, and medical staff training for hospitals and clinics.

Climate Technology (14.6%): Heat pumps and energy recycling systems for industrial, commercial, and residential heating and cooling.

Precision Manufacturing (9.7%): Custom machine parts, semiconductor equipment, and eco-friendly cleaning products for manufacturers and labs.

Technology Solutions (5.5%): Software engineering, product testing, and modernization for businesses needing digital upgrades.

Medical Supplies: Distribution of medical disposables, hospital equipment, and personal protective equipment for healthcare providers.

Dalrada’s Growth Spurt: The Highlights Reel

Acquired IV Services, LLC in May 2024 to expand pharmacy and infusion services.

Launched Dalrada Home Corporation in February 2024 for residential climate technology products.

Signed exclusive distribution deal with Applied Technologies of NY, Inc. in August 2024 for heat pumps.

Expanded manufacturing with new Portland, OR facility lease in August 2024.

Acquired Grand Entrances in August 2024 to grow manufacturing capabilities.

Why Dalrada Catches the Eye

Dalrada operates in the US, UK, India, Malaysia, and Spain, serving both local and international clients. Its in-house engineering and manufacturing teams support product development and maintain an efficient global supply chain. The company’s mix of healthcare, energy, and technology solutions gives it flexibility across changing markets.

Five Things You Need to Know

Revenue was $25.18 million in FY2024, down 15.3% from FY2023.

The Genefic healthcare segment grew 12.3% year-over-year and represented 70.2% of total revenue in FY2024.

Net loss was $23.25 million in FY2024, up from $20.63 million in FY2023.

Cash and cash equivalents were $0.50 million as of FY2024.

Company faces going concern risk due to recurring losses and working capital deficit.

Bottom Line

Dalrada has shifted focus toward healthcare and clean energy, expanding through acquisitions and new products. Its diversified model brings both opportunity and ongoing financial challenges.